Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013, calling it the biggest ...
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...
Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA– Positioned U.S.-based biomanufacturing ...
12don MSN
Sana Biotechnology showcases successful in vivo gene editing of stem cells in Nature publication
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana ...
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...
The promise of genome editing to help understand human diseases and create new therapies is vast, but technological limitations have limited advancement of the field. While existing editing ...
Gene editing is now reaching the mainstream, ushering in a new era of genetic manipulation. Traditionally, inserting or deleting entire genes, regulating their expression, and altering specific ...
On Thursday, Editas Medicine Inc. (NASDAQ:EDIT) announced a strategic realignment to focus on in vivo gene editing. In vivo refers to studies or experiments conducted on living organisms or cells ...
Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...
A multidisciplinary committee of experts studied the scientific underpinnings of human gene-editing technologies, their potential use in biomedical research and medicine -- including human germline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback